Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer

European Urology Oncology(2023)10.1016/j.euo.2023.11.014Source: DataRank Database

Co-occurring BRCA2/SPOP Mutations Predict Exceptional Poly (ADP-ribose) Polymerase Inhibitor Sensitivity in Metastatic Castration-Resistant Prostate Cancer is a research paper published in European Urology Oncology (2023). On theSindex it has a DataRank of 0.442. It has been cited 18 times.

N/A

0.442DataRank · unranked

Scored on demand from live citation data

Open Access18 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (5 grants)Impact (FWCI 3.26)OA: greenTopics (47)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

DataRank Breakdown

Base Score 100%Citation Network 0%

Base Score Contribution

0.442

From this paper's citation signal

Citation Network Contribution

Citation network not refreshed for this result

This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.

Learn more about DataRank methodology →

Authors (37)

Fadi Taza ORCID,Navonil De Sarkar ORCID,Alok K. Tewari ORCID,Syed Arsalan Ahmed Naqvi ORCID,Irbaz Bin Riaz ORCID

Live enrichment

PubMed:38072760 PMC:PMC11162506 OpenAlex:https://openalex.org/W4389504885

NCI NIH HHS

Grant: R01 CA270539

NCI NIH HHS

Grant: R01 CA174777

NCI NIH HHS

Grant: P50 CA097186

NCI NIH HHS

Grant: P30 CA015704

NCI NIH HHS

Grant: P30 CA077598

FWCI

3.26

Citation Percentile

0.9%

Citation Trend

2024

2025

2026

greenLicense: http://www.elsevier.com/open-access/userlicense/1.0/

repositoryhttps://scholarworks.indianapolis.iu.edu/bitstreams/2a0aa437-9fb7-4368-b30f-fe8b47771f86/download

publisherhttps://api.elsevier.com/content/article/PII:S2588931123002778?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2588931123002778?httpAccept=text/plain

repositoryhttps://hdl.handle.net/1805/50893

Fields of Study

Prostate Cancer Treatment and ResearchPARP inhibition in cancer therapyProstate Cancer Diagnosis and TreatmentHumansPoly(ADP-ribose) Polymerase InhibitorsMaleProstatic Neoplasms, Castration-ResistantRetrospective StudiesAgedMutationBRCA2 ProteinMiddle AgedNuclear ProteinsRepressor ProteinsAged, 80 and overNeoplasm Metastasis

MeSH Terms

Poly(ADP-ribose) Polymerase InhibitorsAgedAged, 80 and overHumansMaleMiddle AgedMutationNeoplasm MetastasisNuclear ProteinsRepressor ProteinsRetrospective StudiesBRCA2 ProteinProstatic Neoplasms, Castration-Resistant

Keywords

MedicinePARP inhibitorHazard ratioProstate cancerInternal medicineOncologyProportional hazards modelPoly ADP ribose polymeraseClinical endpointCancerConfidence intervalClinical trialPolymeraseBiologyGeneticsPoly(adp-ribose) Polymerase InhibitorsBrca2 MutationSpop Mutation

Sustainable Development Goals

SDG 0: Good health and well-being